Farmacotoxicologia - Anti-Inflammatory Drug - Medical Science Assignment Help

Assignment Task

Question 1

Molecule X is under development as an anti-inflammatory drug for the treatment of rheumatoid arthritis. Based on the characteristics of disease and of the target patient population describe the preclinical development plan to support the Marketing authorization application (MAA) of X in the each. of the following conditions:

1- X is a synthetic small chemical entity.

2- X is a monoclonal antibody

Question 2

XYZ has been in the market for more than 15 years, for the treatment of HIV-1 infected adults, adolescents, and children of any age.

The content of the original SmPC 4.6 and 5.3 is provided in the Annex 1.

However, recently the Marketing Authorization Holder (MAH) submitted a Type II Variation aiming to update section 4.6 “Pregnancy and lactation” of the XYZ SmPC based on a review of available data in pregnant women on continuous XYZ-based therapy.

To support this request the MHA submitted a clinical review as well as the available studies and supplementary information on this topic were submitted (see Annex 2).

Based on the assessment of the information provided, you are asked to propose an updated content for the SmPC/4.6 section, in line with the appropriate Guideline.

Question 3.

Active Substance AS is being developed as a treatment for hypertension and has tested positive in Ames test. An impurity has been detected, in AS, named impurity X, which was considered structurally alerting (aromatic amine) and was revealed to be positive in an Ames assay, and responsible for the genotoxicity of AS. The level of X in the AS batch 1, to be tested in the FIH trial, is 300 ppm (300µg per 1000 mg).

You are the NC Regulator who will be in charge of assessing the clinical trials of AS. Consider the principles of ICH M7 guideline for the following questions:

1. please discuss the acceptability of the level of impurity X in the batch to be tested in the FIH Trial (batch 1) and which will be the maximum dose of AS acceptable for that trial.

2. Please discuss which will be the maximum duration of a Phase II clinical trial with batch 1 of AS to be tested in a Phase II Clinical trial at a maximum daily dose of 200 mg.

3. Please discuss which measures need to be taken in the production of AS to allow adequate level of X in the product to market at a maximum daily dose of 100mg.

This Medical Science Assignment has been solved by our Medical Science experts at My Uni Paper. Our Assignment Writing Experts are efficient to provide a fresh solution to this question. We are serving more than 10000+ Students in Australia, UK & US by helping them to score HD in their academics. Our Experts are well trained to follow all marking rubrics & referencing style.
Be it a used or new solution, the quality of the work submitted by our assignment experts remains unhampered. You may continue to expect the same or even better quality with the used and new assignment solution files respectively. There’s one thing to be noticed that you could choose one between the two and acquire an HD either way. You could choose a new assignment solution file to get yourself an exclusive, plagiarism (with free Turnitin file), expert quality assignment or order an old solution file that was considered worthy of the highest distinction.